J&J’s Imbruvica scores fifth FDA lymphoma approval
January 20, 2017Medical Communications, Research and Development, Sales and Marketing FDA, Marginal Zone Lymphoma, imbruvica
Johnson & Johnson’s Imbruvica (ibrutinib) has scored its fifth indication approval in the US for the treatment of Marginal Zone …
Top Ten most popular articles on Pharmafile.com this week
January 20, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing top ten
It’s Friday, and there have been some big revelations for the pharma industry this week. Brexit, the ever-present hot topic …
Pharmaceutical R&D tax credit regulatory legislation: The need for clarity
January 20, 2017Medical Communications, Research and Development, Sales and Marketing R&D, pharmafile
Since their introduction in the UK in 2000, R&D tax credits have provided a significant boost to pharmaceutical and biotech …
Sanofi diabetes drug Sulinqua green-lighted in Europe
January 19, 2017Research and Development, Sales and Marketing Sanofi, Sulinqua
Sanofi’s diabetes drug Suliqua has been granted marketing authorisation by the European Commission, giving the go ahead for the launch …
Boehringer steps into Humira race with US and EU biosimilar filings
January 19, 2017Sales and Marketing Boehringer Ingelheim, Humira, biosimilar
Boehringer Ingelheim has just stepped into the ring to battle it out for a slice of Humira’s revenue with accepted …
GSK snatches AZ Europe VP to replace exiting global head of pharma
January 19, 2017Business Services, Medical Communications, Sales and Marketing Abbas Hussain, Luke Miels
GlaxoSmithKline has announced that its global head of pharmaceuticals Abbas Hussain (pictured) is leaving the company; the vacated role will …
Allergan fined £15m over failure to disclose merger discussions
January 19, 2017Sales and Marketing Allergan, SEC
Allergan has been fined $15 million by the Security and Exchange Commission (SEC) after committing disclosure violations during merger talks …
Lilly brings migraine drug home with $960m acquisition
January 19, 2017Sales and Marketing CoLucid Pharmaceuticals, Eli Lilly
Eli Lilly has announced it is to shell out $960 million to snatch up CoLucid Pharmaceuticals and specifically its migraine …
Alcobra axes ADHD drug after Phase 3 failure
January 18, 2017Research and Development ADHD, Alcobra, metadoxine
Israeli-based firm Alcobra is to pull the plug on its experimental attention deficit hyperactivity disorder (ADHD) drug metadoxine after it …
Biogen shells out $1.25bn to protect best-selling MS drug
January 18, 2017Research and Development, Sales and Marketing Biogen, Forward Pharma, multiple sclerosis, tecfidera
Biogen has announced it is to pay $1.25 billion to Copenhagen-based biotech Forward Pharma in the latest development in a …
Researchers financed by pharma more likely to produce positive results, new report says
January 18, 2017Research and Development clinical trials
A new paper published in the British Medical Journal (BMJ) has called the integrity of certain clinical trials into question …
22 pharma companies join forces for global non-communicable disease initiative
January 18, 2017Research and Development BMS, Celgene, Eisai, Eli Lilly, GSK, J&J, JJ, MSD, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda
The World Economic Forum Annual Meeting in Switzerland has seen the launch of Access Accelerated, a global initiative consisting of …
PM May announces Brexit plan, BioIndustry Association CEO reacts
January 18, 2017Research and Development, Sales and Marketing Theresa May, brexit
After months of uncertainty following the UK’s vote to leave the EU, Theresa May has finally announced the first inklings …
Centre for Process Innovation to support pharma SMEs
January 17, 2017Manufacturing and Production, Medical Communications, Research and Development CPI, Centre for Process Innovation
The Centre for Process Innovation is targeting small and medium-sized enterprises from the pharmaceutical and chemical industries with its Innovation …
SMC rejects Janssen’s multiple myeloma treatment Darzalex
January 17, 2017Manufacturing and Production, Sales and Marketing Janssen, SMC, darzalex
The Scottish Medicines Consortium (SMC) has decided not to recommend Janssen’s Darzalex (daratumumab) for routine use by NHS Scotland as …
Merck forges data analytics partnership with Palantir
January 17, 2017Manufacturing and Production, Research and Development, Sales and Marketing Merck, Palantir
Merck has teamed up with software and data-mining firm Palantir with the intention to utilise its data analytics services to …
AZ to rework ongoing immuno-oncology trials to “enhance options”
January 17, 2017Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, non-small cell lung cancer
Due to the “strong efficacy” shown by its durvalumab as a treatment for non-small cell lung cancer (NSCLC), AstraZeneca has …
New NICE ultra-rare disease proposals “not fit for purpose”, says BIA
January 16, 2017Manufacturing and Production BioIndustry Association, NICE
The BioIndustry Association (BIA) has accused new proposals put forward by the National Institute for Health and Care Excellence (NICE) …
Benzodiazepines increase stroke risk in Alzheimer’s patients, study finds
January 16, 2017Research and Development, Sales and Marketing Alzheimer's, Alzheimers, benzodiazepines
Benzodiazepines and similar drugs could increase the risk of strokes in Alzheimer’s patients by as much as 20% according to …
J&J to reveal drug price increases next month
January 16, 2017Sales and Marketing Johnson & Johnson
Next month, Johnson & Johnson will reveal the average price increases of its prescription drugs in a move to increase …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
